KR102255753B1 - 뮤신 관련 질환의 치료 - Google Patents

뮤신 관련 질환의 치료 Download PDF

Info

Publication number
KR102255753B1
KR102255753B1 KR1020157018076A KR20157018076A KR102255753B1 KR 102255753 B1 KR102255753 B1 KR 102255753B1 KR 1020157018076 A KR1020157018076 A KR 1020157018076A KR 20157018076 A KR20157018076 A KR 20157018076A KR 102255753 B1 KR102255753 B1 KR 102255753B1
Authority
KR
South Korea
Prior art keywords
cancer
composition
pharmaceutically acceptable
nac
mucin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157018076A
Other languages
English (en)
Korean (ko)
Other versions
KR20150096445A (ko
Inventor
데이비드 엘. 모리스
로거 에스턴
자베드 아크터
크리쉬나 필라이
Original Assignee
뉴사우스 이노베이션즈 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012905519A external-priority patent/AU2012905519A0/en
Application filed by 뉴사우스 이노베이션즈 피티와이 리미티드 filed Critical 뉴사우스 이노베이션즈 피티와이 리미티드
Publication of KR20150096445A publication Critical patent/KR20150096445A/ko
Application granted granted Critical
Publication of KR102255753B1 publication Critical patent/KR102255753B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
KR1020157018076A 2012-12-17 2013-12-17 뮤신 관련 질환의 치료 Active KR102255753B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012905519A AU2012905519A0 (en) 2012-12-17 Treatment of diseases involving mucin
AU2012905519 2012-12-17
PCT/AU2013/001474 WO2014094041A1 (en) 2012-12-17 2013-12-17 Treatment of diseases involving mucin

Publications (2)

Publication Number Publication Date
KR20150096445A KR20150096445A (ko) 2015-08-24
KR102255753B1 true KR102255753B1 (ko) 2021-05-26

Family

ID=50977393

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157018076A Active KR102255753B1 (ko) 2012-12-17 2013-12-17 뮤신 관련 질환의 치료

Country Status (13)

Country Link
US (2) US11369666B2 (enExample)
EP (1) EP2931296B1 (enExample)
JP (1) JP6502853B2 (enExample)
KR (1) KR102255753B1 (enExample)
CN (2) CN116077631A (enExample)
AU (3) AU2013362878B2 (enExample)
CA (1) CA2895149C (enExample)
DK (1) DK2931296T3 (enExample)
ES (1) ES2727686T3 (enExample)
NZ (1) NZ631536A (enExample)
TR (1) TR201907858T4 (enExample)
WO (1) WO2014094041A1 (enExample)
ZA (1) ZA201503979B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992122A1 (en) 2015-07-16 2017-01-19 Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center Compositions and methods for treating peritoneal cancers
US11364286B2 (en) 2015-10-14 2022-06-21 Newsouth Innovations Pty Limited Compositions and methods for the treatment of diseases involving mucin
WO2017195792A1 (ja) * 2016-05-13 2017-11-16 国立大学法人熊本大学 新規なｐｅｇ修飾酵素及びそれを用いた抗がん剤デリバリー
CN108066413A (zh) * 2016-11-15 2018-05-25 李雁 标准桃金娘油的癌性黏液溶解作用及抗肿瘤新用途
CN112236171A (zh) * 2018-02-23 2021-01-15 Muc制药有限公司 含有影响粘蛋白的蛋白酶的制剂
AU2020231396B2 (en) 2019-03-07 2025-03-20 Nobo Medicine Inc. Caspase inhibitors and methods of use thereof
EP3797783A1 (en) 2019-09-27 2021-03-31 Freie Universität Berlin Novel medical uses of thiol-functionalized polyglycerol derivatives
EP4142774A4 (en) * 2020-05-01 2024-05-29 Mucpharm Pty Ltd PREVENTION AND TREATMENT OF VIRUS INFECTIONS
IL302075A (en) 2020-10-19 2023-06-01 Mediwound Ltd Methods of treating skin cancers
EP4422673A4 (en) * 2021-10-27 2025-07-30 MUCPharm Pty Ltd METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2024094085A1 (zh) * 2022-11-01 2024-05-10 孙正龙 一种选择性降解粘蛋白的丝氨酸蛋白酶及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075710A1 (en) 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
JP2011026293A (ja) 2009-07-24 2011-02-10 Taipei Veterans General Hospital 神経傷害の処置におけるシリマリンおよびシリビンの使用
JP2011132144A (ja) 2009-12-22 2011-07-07 National Agriculture & Food Research Organization 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH08337532A (ja) * 1995-06-14 1996-12-24 Takeda Chem Ind Ltd 医薬組成物
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
CH695414A5 (de) * 2001-05-30 2006-05-15 Guenter Holzner Kosmetische Präparate gegen die Alterung der menschlichen Haut in einer Mehrkammer-Mischpackung.
US6517832B1 (en) * 2001-08-24 2003-02-11 Jeffrey L. Marrongelle Formulations and methods for treating chronic migraine
DK1694137T3 (da) * 2003-11-26 2009-04-27 Hills Pet Nutrition Inc Fremgangsm de til at reducere lugt af aff ring fra k ledyr
CN1838969A (zh) * 2004-10-07 2006-09-27 三仪股份有限公司 经皮和经粘膜制剂
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
CN103285383B (zh) * 2013-06-03 2015-01-07 海南通用同盟药业有限公司 一种包含菠萝蛋白酶的药物组合物及菠萝蛋白酶肠溶片

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080075710A1 (en) 2006-09-25 2008-03-27 Liquid Potions Llc Herbal composition for treating hangovers
US20100166726A1 (en) * 2007-03-07 2010-07-01 Northeastern University Compositions for improving cellular uptake of a chemotherapeutic agent in a cell exhibiting mucin deregulation
JP2011026293A (ja) 2009-07-24 2011-02-10 Taipei Veterans General Hospital 神経傷害の処置におけるシリマリンおよびシリビンの使用
JP2011132144A (ja) 2009-12-22 2011-07-07 National Agriculture & Food Research Organization 穀物由来のプロアントシアニジン含有抽出物、及びその製造方法

Also Published As

Publication number Publication date
EP2931296A1 (en) 2015-10-21
US20220401529A1 (en) 2022-12-22
AU2013362878A1 (en) 2015-06-18
JP6502853B2 (ja) 2019-04-17
TR201907858T4 (tr) 2019-06-21
JP2016502981A (ja) 2016-02-01
AU2013362878B2 (en) 2017-03-30
AU2019203315A1 (en) 2019-05-30
HK1211213A1 (en) 2016-05-20
ES2727686T3 (es) 2019-10-17
NZ631536A (en) 2016-12-23
CN116077631A (zh) 2023-05-09
ZA201503979B (en) 2017-11-29
AU2017204436A1 (en) 2017-07-20
AU2017204436B2 (en) 2019-05-30
DK2931296T3 (da) 2019-06-03
KR20150096445A (ko) 2015-08-24
EP2931296A4 (en) 2016-08-10
US11369666B2 (en) 2022-06-28
CN104968358B (zh) 2022-11-18
EP2931296B1 (en) 2019-02-27
CA2895149C (en) 2023-08-22
US20150343035A1 (en) 2015-12-03
CN104968358A (zh) 2015-10-07
WO2014094041A1 (en) 2014-06-26
CA2895149A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
US20220401529A1 (en) Treatment of diseases involving mucin
US10010542B2 (en) PFKFB3 inhibit and methods of use as an anti-cancer therapeutic
KR102271848B1 (ko) 암 치료용 약학적 배합물
KR20140145604A (ko) 암 치료용 키나제 저해제
EP2902028A1 (en) Drug composition for treating tumors and application thereof
US11364286B2 (en) Compositions and methods for the treatment of diseases involving mucin
CN104619325A (zh) 治疗肿瘤的组合药物及其应用
HK1211213B (en) Treatment of diseases involving mucin
US20250221967A1 (en) Compositions and methods for the treatment of cancer and other proliferative diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150706

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20170310

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181106

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200113

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20201124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200113

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20201124

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200629

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150720

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210223

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210128

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201124

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200629

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150720

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210518

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210518

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240508

Start annual number: 4

End annual number: 4